<- Go Home
Bentley Pharmaceuticals, Inc.
As of July 22, 2008, Bentley Pharmaceuticals, Inc. was acquired by Teva Pharmaceutical Industries Limited. Bentley Pharmaceuticals, Inc., through its subsidiaries, engages in the research, development, licensing, and commercialization of generic and branded pharmaceutical products, active pharmaceutical ingredients, and drug delivery technologies. It offers pharmaceuticals for the treatment of cardiovascular, gastrointestinal, infectious, and central nervous system diseases in Europe. The company was founded in 1974 and is headquartered in Exeter, New Hampshire.
Market Cap
$337.0M
Volume
130.8K
Cash and Equivalents
$33.3M
EBITDA
$19.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$65.2M
Profit Margin
48.95%
52 Week High
$16.39
52 Week Low
$9.05
Dividend
N/A
Price / Book Value
2.67
Price / Earnings
238.98
Price / Tangible Book Value
3.10
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
$13.0M
Return on Equity
1.21%
Return on Assets
4.96
Cash and Short Term Investments
$34.4M
Debt
$17.6M
Equity
$124.9M
Revenue
$133.3M
Unlevered FCF
-$5.2M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium